{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:56:11Z","timestamp":1769147771816,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.contraception.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T17:08:58Z","timestamp":1524330538000},"page":"120-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18\u201344: A retrospective claims database analysis"],"prefix":"10.1016","volume":"98","author":[{"given":"Amy","family":"Law","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avin","family":"Yaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2018.04.006_bb0005","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011","volume":"374","author":"Finer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2018.04.006_bb0010","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2018.04.006_bb0015","first-page":"1","article-title":"U.S. selected practice recommendations for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2018.04.006_bb0020","first-page":"1173","article-title":"ACOG Practice Bulletin No. 186 Summary: Long-acting reversible contraception: Implants and intrauterine devices","volume":"130","author":"American College of Obstetricians and Gynecologists","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0025","doi-asserted-by":"crossref","first-page":"761.e1-8","DOI":"10.1016\/j.ajog.2014.12.028","article-title":"Complications and continuation rates associated with 2 types of long-acting contraception","volume":"212","author":"Berenson","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0030","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/AOG.0b013e31827499bd","article-title":"Continuation of reversible contraception in teenagers and young women","volume":"120","author":"Rosenstock","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0035","doi-asserted-by":"crossref","first-page":"662.e1-8","DOI":"10.1016\/j.ajog.2015.08.001","article-title":"Three-year continuation of reversible contraception","volume":"213","author":"Diedrich","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0040","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/AOG.0b013e3182a91f45","article-title":"Twenty-four-month continuation of reversible contraception","volume":"122","author":"O'neil-Callahan","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0045","series-title":"Highlights of Prescribing Information: SKYLA","year":"2016"},{"key":"10.1016\/j.contraception.2018.04.006_bb0050","series-title":"Highlights of Prescribing Information: Nexplanon","year":"2015"},{"key":"10.1016\/j.contraception.2018.04.006_bb0055","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000000019","article-title":"Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial","volume":"122","author":"Nelson","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0060","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","article-title":"A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena","volume":"97","author":"Gemzell-Danielsson","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2018.04.006_bb0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12703\/P6-113","article-title":"Recent advances in contraception","volume":"6","author":"Aiken","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.contraception.2018.04.006_bb0070","doi-asserted-by":"crossref","first-page":"e0135309","DOI":"10.1371\/journal.pone.0135309","article-title":"The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial","volume":"10","author":"Gemzell-Danielsson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.04.006_bb0075","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/humrep\/14.4.976","article-title":"A multicentre efficacy and safety study of the single contraceptive implant Implanon\u00ae","volume":"14","author":"Croxatto","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2018.04.006_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.fertnstert.2016.02.036","article-title":"A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant","volume":"106","author":"Apter","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2018.04.006_bb0085","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/AOG.0000000000000279","article-title":"Receipt of prescription contraception by commercially insured women with chronic medical conditions","volume":"123","author":"DeNoble","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0090","first-page":"1","article-title":"Current contraceptive use in the United States, 2006\u20132010, and changes in patterns of use since","volume":"2012","author":"Jones","year":"1995","journal-title":"Natl Health Stat Report"},{"key":"10.1016\/j.contraception.2018.04.006_bb0095","first-page":"1","article-title":"Current contraceptive status among women aged 15\u201344: United States, 2011\u20132013","author":"Daniels","year":"2014","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.contraception.2018.04.006_bb0100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/AOG.0000000000001094","article-title":"Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009\u20132012","volume":"126","author":"Kavanaugh","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.04.006_bb0105","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2105\/AJPH.2013.301416","article-title":"Shifts in intended and unintended pregnancies in the United States, 2001\u20132008","volume":"104","author":"Finer","year":"2014","journal-title":"Am J Public Health"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418301422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418301422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T16:06:31Z","timestamp":1530720391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782418301422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0010782418301422"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2018.04.006","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18\u201344: A retrospective claims database analysis","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}